Kimberly Chong

Array ( [id] => 9269781 [patent_doc_number] => 20140024700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-23 [patent_title] => 'BLOOD-BORNE MIRNAS AS SURROGATE MARKERS OF DRUG EFFICACY FOR CARDIAC CONDITIONS' [patent_app_type] => utility [patent_app_number] => 13/994622 [patent_app_country] => US [patent_app_date] => 2011-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 21063 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13994622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9122337 [patent_doc_number] => 20130289259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'APTAMER LABELLED WITH F-19 NUCLEUS FOR TARGETED MOLECULAR IMAGING BY MRI' [patent_app_type] => utility [patent_app_number] => 13/991650 [patent_app_country] => US [patent_app_date] => 2011-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3911 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13991650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8858790 [patent_doc_number] => 08461325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-11 [patent_title] => 'Oligomers' [patent_app_type] => utility [patent_app_number] => 13/307825 [patent_app_country] => US [patent_app_date] => 2011-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17727 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13307825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9074593 [patent_doc_number] => 08552172 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-08 [patent_title] => 'Oligomers' [patent_app_type] => utility [patent_app_number] => 13/307926 [patent_app_country] => US [patent_app_date] => 2011-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17789 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13307926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10870313 [patent_doc_number] => 08895509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-25 [patent_title] => 'MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells' [patent_app_type] => utility [patent_app_number] => 13/989312 [patent_app_country] => US [patent_app_date] => 2011-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 19135 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13989312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10110153 [patent_doc_number] => 09145557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-29 [patent_title] => 'Oligonucleotides for modulation of target RNA activity' [patent_app_type] => utility [patent_app_number] => 13/989128 [patent_app_country] => US [patent_app_date] => 2011-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7923 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13989128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9937419 [patent_doc_number] => 08987225 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-24 [patent_title] => 'Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG' [patent_app_type] => utility [patent_app_number] => 13/989124 [patent_app_country] => US [patent_app_date] => 2011-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 26649 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13989124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9844271 [patent_doc_number] => 08946187 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-03 [patent_title] => 'Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer' [patent_app_type] => utility [patent_app_number] => 13/884668 [patent_app_country] => US [patent_app_date] => 2011-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 22 [patent_no_of_words] => 15090 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9263357 [patent_doc_number] => 20130345286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-26 [patent_title] => 'LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES' [patent_app_type] => utility [patent_app_number] => 13/884601 [patent_app_country] => US [patent_app_date] => 2011-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 44285 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10115992 [patent_doc_number] => 09150864 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-06 [patent_title] => 'Methods for modulating factor 12 expression' [patent_app_type] => utility [patent_app_number] => 13/884067 [patent_app_country] => US [patent_app_date] => 2011-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23930 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10039475 [patent_doc_number] => 09080174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-14 [patent_title] => 'HBV treatment' [patent_app_type] => utility [patent_app_number] => 13/882124 [patent_app_country] => US [patent_app_date] => 2011-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 15 [patent_no_of_words] => 21745 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13882124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9483091 [patent_doc_number] => 08729042 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-20 [patent_title] => 'Treating ocular diseases using peroxisome proliferator—activated receptor delta antagonists' [patent_app_type] => utility [patent_app_number] => 13/281290 [patent_app_country] => US [patent_app_date] => 2011-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 22717 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13281290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8265960 [patent_doc_number] => 20120165389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-28 [patent_title] => 'ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME' [patent_app_type] => utility [patent_app_number] => 13/277975 [patent_app_country] => US [patent_app_date] => 2011-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7194 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13277975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10032898 [patent_doc_number] => 09074207 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-07 [patent_title] => 'Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy' [patent_app_type] => utility [patent_app_number] => 13/878355 [patent_app_country] => US [patent_app_date] => 2011-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 6821 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13878355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8834718 [patent_doc_number] => 08450474 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-05-28 [patent_title] => 'Antisense oligonucleotides for inducing exon skipping and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 13/270500 [patent_app_country] => US [patent_app_date] => 2011-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20726 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13270500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7744662 [patent_doc_number] => 20120022144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-26 [patent_title] => 'Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/270744 [patent_app_country] => US [patent_app_date] => 2011-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20178 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13270744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7757169 [patent_doc_number] => 20120029058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-02 [patent_title] => 'Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/270531 [patent_app_country] => US [patent_app_date] => 2011-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 20171 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13270531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8920973 [patent_doc_number] => 08486907 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-16 [patent_title] => 'Antisense oligonucleotides for inducing exon skipping and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 13/270992 [patent_app_country] => US [patent_app_date] => 2011-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20734 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13270992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7744666 [patent_doc_number] => 20120022145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-26 [patent_title] => 'Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/271080 [patent_app_country] => US [patent_app_date] => 2011-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20167 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13271080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7757173 [patent_doc_number] => 20120029059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-02 [patent_title] => 'Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/270937 [patent_app_country] => US [patent_app_date] => 2011-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20168 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13270937 [rel_patent_id] =>[rel_patent_doc_number] =>)